Management of patients with community-acquired pneumonia treated in hospital in Sweden

Scandinavian Journal of Infectious Diseases

Volumn 34, Issue 12, 2002, Pages 887-892

  Hedlund, Jonas ^a   Örtqvist, Åke ^a   Ahlqvist, Thomas ^b   Augustinsson, Åsa ^b   Beckman, Hans ^b   Blanck, Charlotta ^b   Burman, Lars Å ^b   Claesson, Bo ^b   Qvarfordt, Ingemar ^b   Elbel, Elisabeth ^b   Erntell, Mats ^b   Follin, Per ^b   Goscinski, Gunilla ^b   Holmberg, Hans ^b   Höfer, Margareta ^b   Jorup, Christina ^b   Lidman, Christer ^b   Lindhusen, Eva ^b   Rensfeldt, Gunilla ^b   Rosenkvist, Elisabeth ^b   Stenlund, Göran ^b   Stålberg, Åke ^b   Verngren, Karin ^b   Vig, Ivan ^b   Wendahl, Suzanne ^b   more..

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMINOPENICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; MACROLIDE; PENICILLIN G; TETRACYCLINE;

ANTIMICROBIAL THERAPY; ARTICLE; BLOOD CULTURE; COHORT ANALYSIS; COMORBIDITY; DEMOGRAPHY; DISEASE SEVERITY; DRUG CHOICE; HOSPITAL CARE; HOSPITAL DEPARTMENT; HOSPITALIZATION; HUMAN; LABORATORY TEST; LENGTH OF STAY; MEDICAL RECORD; MICROBIOLOGICAL EXAMINATION; MONOTHERAPY; MORTALITY; MULTICENTER STUDY; OUTCOMES RESEARCH; PATIENT CARE; PHYSICAL EXAMINATION; PNEUMONIA; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; SPUTUM CULTURE; STREPTOCOCCUS PNEUMONIAE; SWEDEN; TREATMENT OUTCOME;

ADOLESCENT; AGED; CEPHALOSPORINS; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HAEMOPHILUS INFLUENZAE; HOSPITALIZATION; HUMANS; MALE; MYCOPLASMA PNEUMONIAE; PENICILLINS; PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SWEDEN; TREATMENT OUTCOME;

EID: 0036989686     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/0036554021000026965     Document Type: Article

References (45)

1. Jokinen C, Heiskanen L, Juvonen H, Kallinen S, Karkola K, Korppi M, et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 1993; 137: 977-88.
2. Marrie T. Community-acquired pneumonia. J Clin Infect Dis 1994; 18: 501-13.
3. Woodhead MA, Macfarlane JT. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987; i: 671-4.
4. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820-37.
5. British Thoracic Society. BTS guidelines for the management of community-acquired pneumonia in adults. Thorax 2001; 56 (Suppl IV): iv1-64.
6. Marston BJ, Plouffe JE, File TM, Hackman BA, Salstrom S-J, Lipman HB, et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio. Arch Intern Med 1997; 157: 1709-18.
7. American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418-26.
8. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-54.
9. Bartlett JG, Breiman RF, Mandell LA, File TM. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998; 26: 811-38.
10. Bartlett JG, Dowell SF, Mandell LA, File TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347-82.
11. Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance. Arch Intern Med 2000; 160: 1399-408.
12. Mandell LA, Niederman M. Antimicrobial treatment of community-acquired pneumonia in adults: a conference report. Can J Infect Dis 1993; 4: 25-8.
13. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000; 31: 383-421.
14. British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Br J Hosp Med 1993; 49: 346-50.
15. European Study on Community Acquired Pneumonia (ESO-CAP) Committee. Management of adult community-acquired lower respiratory tract infections. Eur Respir Rev 1998; 8: 391-426.
16. Huchon GJ, Gialdroni-Grassi G, Léophonte P, Manresa F, Schaberg T, Woodhead M. Initial antibiotic therapy for lower respiratory tract infection in the community: a European survey. Eur Respir J 1996; 9: 1590-5.
17. Örtqvist A. In-hospital management of adults who have community-acquired pneumonia. Semin Respir Infect 1999; 14: 135-50.
18. Örtqvist Å. Antibiotic treatment of community-acquired pneumonia in clinical practice: a European perspective. J Antimicrob Chemother 1995; 35: 205-12.
19. Mölstad S, Stålsby Lundborg C, Karlsson A-K, Cars O. Antibiotic prescription rates vary markedly between 13 European countries. Scand J Infect Dis 2002; 34: 366-71.
20. Cars O, Mölstad S, Melander A. Variation in antibiotic use in the European Union. Lancet 2001; 357: 1851-3.
21. Kirk O, Glenthöj J, Dragsted UB, Helweg-Larsen J, Aru TM, Benfield TL, et al. Penicillin as empirical therapy for patients hospitalized with community-acquired pneumonia at a Danish hospital. Dan Med Bull 2001; 48: 84-8.
22. Stahl JE, Barza M, DesJardin J, Martin R, Eckman MH. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999; 159: 2576-80.
23. Gleason PP, Kapoor WN, Stone RA, Lave JR, Obrosky DS, Schulz R, et al. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. JAMA 1997; 278: 32-9.
24. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159: 2562-72.
25. Houck PM, MacLehose MS, Niederman MS, Lowery JK. Empiric antibiotic therapy and mortality among Medicare pneumonia inpatients in 10 western states. Chest 2001; 119: 1420-6.
26. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161: 1837-42.
27. McCormick D, Fine MJ, Coley CM, Marrie TJ, Lave JR, Obrosky S, Kapoor WN. Variation in length of hospital stay in patients with community-acquired pneumonia: are shorter stays associated with worse medical outcomes? Am J Med 1999; 107: 5-12.
28. Halm EA, Fine MJ, Marrie TJ, Coley CM, Kapoor WN, Obrosky S, Singer DE. Time to clinical stability in patients hospitalized with community-acquired pneumonia. Implications for practice guidelines. JAMA 1998; 279: 1452-7.
29. Fine MJ, Singer DE, Phelps AL, Hanusa BH, Kapoor WN. Differences in length of hospital stay in patients with community-acquired pneumonia: a prospective four-hospital study. Med Care 1993; 31: 371-80.
30. Fine MJ, Singer DE, Hanusa BH, Lave JR, Kapoor WN. Validation of a pneumonia prognostic index using the Medis-Groups Comparative Hospital Database. Am J Med 1993; 94: 153-9.
31. Feagan BG, Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK. Treatment and outcomes of community-acquired pneumonia at Canadian hospitals. Can Med Assoc J 2000; 162: 1415-20.
32. Örtqvist Å, Hedlund J, Wretlind B, Carlström A, Kalin M. Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia. Scand J Infect Dis 1995; 27: 457-62.
33. Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997; 278: 2080-4.
34. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-50.
35. Fine MJ, Stone RA, Singer DE, Coley CM, Marrie TJ, Lave JR, et al. Processes and outcomes of care for patients with community-acquired pneumonia. Results from the pneumonia patients outcomes research team (PORT) cohort study. Arch Intern Med 1999; 159: 970-80.
36. Harrison BDW, Farr BM, Pugh S, Selkon JB. Community-acquired pneumonia in adults in British hospitals in 1982-1983: a survey of aetiology, mortality, prognostic factors and outcome. Q J Med New Series 1987; 62: 195-220.
37. Hedlund J, Örtqvist Å, Kalin M. Nasopharyngeal culture in the pneumonia diagnosis. Infection 1990; 18: 283-5.
38. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, Kapoor WN. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275: 134-41.
39. Mundy L, Oldach D, Auwaerter PG, Gaydos CA, Moore RD, Bartlett JG, Quinn TC. Implications for macrolide treatment in community-acquired pneumonia. Chest 1998; 113: 1201-6.
40. Kalin M, Örtqvist Å, Almela M, Aufwerber E, Dwyer R, Henriques B, et al. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis 2000; 182: 840-7.
41. Örtqvist Å, Kalin M, Julander I, Mufson M. Deaths in bacteremic pneumococcal pneumonia. Chest 1993; 103: 710-6.
42. Burns LR, Wholey DR. The effects of patient, hospital, and physician characteristics on length of stay and mortality. Med Care 1991; 29: 251-71.
43. Lave JR, Leinhardt S. The cost and length of a hospital stay. Inquiry 1976; 13: 327-43.
44. Sanyal S, Smith PR, Saba AC, Gupta S, Berkowitz L, Homel P. Initial microbiologic studies did not affect outcome in adults hospitalized with community-acquired pneumonia. Am J Respir Crit Care Med 1999; 160: 346-8.
45. Chalasani NP, Valdecanas MAL, Gopal AK, McCowan JE, Jurado RL. Clinical utility of blood cultures in adult patients with community-acquired pneumonia without defined underlying risks. Chest 1995; 108: 932-6.